血清TSGF、AFP、VEGF在原发性肝癌治疗疗效评价中的价值  

Value of serum TSGF,AFP,VEGF in curative effect evaluation of primary hepatic carcinoma

作　　者：孟素玲[1] 

机构地区：[1]厦门市第三医院检验科,福建厦门361100

出　　处：《国际检验医学杂志》2016年第3期329-330,共2页International Journal of Laboratory Medicine

摘　　要：目的探讨血清肿瘤特异性生长因子(TSGF)、甲胎蛋白(AFP)、血管内皮生长因子(VEGF)在评价原发性肝癌(PHC)治疗疗效中的价值。方法选取PHC患者75例,于治疗前1d、治疗后4d及治疗后28d分别检测血清TSGF、AFP、VEGF水平。分析治疗前1d血清VEGF与AFP水平的关系。结果 75例PHC患者治疗后4、28d的TSGF、AFP、VEGF水平均明显低于治疗前1d,差异有统计学意义(P<0.05)。AFP≥400ng/mL与AFP<400ng/mL患者的VEGF水平差异无统计学意义(P>0.05)。结论 TSGF、AFP、VEGF可作为评价PHC预后的指标。Objective To explore the evaluation of tumor specific growth factor（TSGF）,alpha-fetoprotein （AFP） and vascular endothelial cell growth factor（VEGF） levels in therapeutic effect of primary hepatic carcinoma （PHC）. Methods Serum TSGF, AFP and VEGF levels were detected on 1 d before treatment,4,28 d after treatment in 75 patients with PHC. The relation between serum VEGF with AFP on 1 d before treatment was analyzed. Results The levels of serum TSGF, AFP and VEGF on 4,28 d after treatment in 75 cases of PHC were significantly lower than those on 1 d before treatment, the difference was statistically significant （P〈0, 05）. The VEGF level had no statistical difference between the patients with AFP≥400 ng/mL and the patients with AFP（ 400 ng/mL（P〉0.05）. Conclusion TSGF,AFP and VEGF can serve as the indicators for evaluating PHC prognosis.

关 键 词：原发性肝癌 肿瘤特异性生长因子 甲胎蛋白 血管内皮细胞生长因子 

分 类 号：R735.7[医药卫生—肿瘤] R730.43[医药卫生—临床医学]